167 related articles for article (PubMed ID: 25998230)
1. Use of juvenile animal studies to support oncology medicine development in children.
Duarte DM
Reprod Toxicol; 2015 Aug; 56():97-104. PubMed ID: 25998230
[TBL] [Abstract][Full Text] [Related]
2. An update of juvenile animal studies in the European Union: What do the numbers say?
Hurtt ME; Engel S
Reprod Toxicol; 2015 Aug; 56():105-8. PubMed ID: 25937597
[TBL] [Abstract][Full Text] [Related]
3. Juvenile animal studies in the development of pediatric medicines: experience from European medicines and pediatric investigation plans.
Duarte DM; Silva-Lima B
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):353-8. PubMed ID: 21594973
[TBL] [Abstract][Full Text] [Related]
4. Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials.
Visalli T; Bower N; Kokate T; Andrews PA
Regul Toxicol Pharmacol; 2018 Jul; 96():167-177. PubMed ID: 29763632
[TBL] [Abstract][Full Text] [Related]
5. The need for juvenile animal studies--a critical review.
Soellner L; Olejniczak K
Regul Toxicol Pharmacol; 2013 Feb; 65(1):87-99. PubMed ID: 23108189
[TBL] [Abstract][Full Text] [Related]
6. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European Medicines Agency workshop on juvenile animal testing for nonclinical assessors.
Silva-Lima B; Due Theilade-Thomsen M; Carleer J; Vidal JM; Tomasi P; Saint-Raymond A
Birth Defects Res B Dev Reprod Toxicol; 2010 Dec; 89(6):467-73. PubMed ID: 20632393
[TBL] [Abstract][Full Text] [Related]
7. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
Carleer J; Karres J
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
[TBL] [Abstract][Full Text] [Related]
8. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
9. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
[TBL] [Abstract][Full Text] [Related]
10. Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label.
Baldrick P
Ther Innov Regul Sci; 2018 Sep; 52(5):641-648. PubMed ID: 29714556
[TBL] [Abstract][Full Text] [Related]
11. The evolution of juvenile animal testing for small and large molecules.
Baldrick P
Regul Toxicol Pharmacol; 2013 Nov; 67(2):125-35. PubMed ID: 23896345
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory Perspective.
van der Laan JW; van Malderen K; de Jager N; Duarte D; Egger GF; Lavergne F; Roque CG; Vieira I; Wiesner L; Carleer J
Int J Toxicol; 2019; 38(6):456-475. PubMed ID: 31662008
[TBL] [Abstract][Full Text] [Related]
13. Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development.
Barrow PC; Schmitt G
Methods Mol Biol; 2017; 1641():25-67. PubMed ID: 28748457
[TBL] [Abstract][Full Text] [Related]
14. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
15. Toxicology testing in drug discovery and development.
Dorato MA; Buckley LA
Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
[TBL] [Abstract][Full Text] [Related]
16. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
17. Juvenile animal testing of hydroxypropyl-β-cyclodextrin in support of pediatric drug development.
De Schaepdrijver L; Mariën D; Rhimi C; Voets M; van Heerden M; Lammens L
Reprod Toxicol; 2015 Aug; 56():87-96. PubMed ID: 26013174
[TBL] [Abstract][Full Text] [Related]
18. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
Stefanska AM; Distlerová D; Musaus J; Olski TM; Dunder K; Salmonson T; Mentzer D; Müller-Berghaus J; Hemmings R; Veselý R
Arch Dis Child; 2017 Oct; 102(10):952-957. PubMed ID: 28554892
[TBL] [Abstract][Full Text] [Related]
19. Juvenile animal toxicity study designs to support pediatric drug development.
Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
[TBL] [Abstract][Full Text] [Related]
20. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
[Next] [New Search]
